# A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

> **NCT02805179** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Glioma

## Interventions

- **RADIATION:** High Dose Radiation
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02805179
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-22
- **Primary completion:** 2020-02-06
- **Final completion:** 2020-11-18
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805179, "A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02805179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*